Study guide

15.4 Critical Appraisal of Nutrition Research & Evidence

Certified Nutrition Support Clinician CNSC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Nutrition Screening, Dietary Evaluation & Energy Requirements

1.1 Nutrition Screening & Validated Risk Tools 1.2 Dietary History & Nutrient Intake Assessment 1.3 Energy Expenditure Estimation & Indirect Calorimetry

2 Chapter 2: Macronutrients, Micronutrients & Fluid Management

2.1 Protein Requirements & Nitrogen Balance 2.2 Fluid Requirements & Electrolyte Homeostasis 2.3 Essential Vitamins & Trace Elements

3 Chapter 3: Anthropometrics, Physical Exam & Malnutrition Consensus

3.1 Anthropometric Assessment & Body Composition 3.2 Nutrition-Focused Physical Examination (NFPE) 3.3 AND/ASPEN & GLIM Malnutrition Criteria

4 Chapter 4: Pediatric & Specialized Nutrition Assessment

4.1 Pediatric & Neonatal Nutrition Assessment 4.2 Biochemical Assessment, Visceral Proteins & Inflammation

5 Chapter 5: Enteral Nutrition Access & Tube Management

5.1 Enteral Access Modalities & Route Selection 5.2 Tube Placement Verification & Stoma Site Care

6 Chapter 6: Enteral Formulation, Regimen Design & Administration

6.1 Enteral Formula Classification & Selection 6.2 Enteral Delivery Methods & Infusion Schedules 6.3 Enteral Fluid Management & Free Water Requirements

7 Chapter 7: Enteral Complications & Medication Administration

7.1 Enteral Gastrointestinal Complications 7.2 Enteral Metabolic, Mechanical & Pulmonary Complications 7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

8 Chapter 8: Parenteral Nutrition Indications, Access & Formulation Design

8.1 Parenteral Nutrition Indications & Venous Access Routes 8.2 Peripheral Parenteral Nutrition (PPN) Parameters 8.3 Central PN Macronutrient Formulation

9 Chapter 9: Parenteral Additives, Compounding & Physical Stability

9.1 Parenteral Electrolytes, Trace Elements & Vitamins 9.2 Calcium-Phosphate Solubility & Precipitation Risks 9.3 Physical Stability, Total Nutrient Admixtures & Filtration

10 Chapter 10: Parenteral Complications, CLABSI & Organ Toxicities

10.1 Central Line-Associated Bloodstream Infections & Mechanical Risks 10.2 Refeeding Syndrome Pathophysiology & Prevention 10.3 Parenteral Nutrition-Associated Liver Disease & Metabolic Bone Disease

11 Chapter 11: Critical Care, Obesity & Pulmonary Nutrition Support

11.1 Critical Illness, Sepsis & Trauma Nutrition 11.2 Nutrition Support in Obesity & Hypocaloric Feeding 11.3 Pulmonary Failure & Mechanical Ventilation 11.4 Nutrition Support Care Plans, Goals & Therapy Reassessment

12 Chapter 12: Organ Failure: Renal, Hepatic & Gastrointestinal Support

12.1 Acute Kidney Injury & Renal Replacement Therapy 12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis 12.3 Short Bowel Syndrome & Intestinal Failure

13 Chapter 13: Oncology, Surgical Care & Intestinal Failure

13.1 Oncology Nutrition & Cancer Cachexia 13.2 Perioperative Nutrition & Enhanced Recovery After Surgery (ERAS) 13.3 Enterocutaneous Fistulas & Severe Malabsorption

14 Chapter 14: Process Management, Compounding Safety & Home Nutrition Support

14.1 PN Order Verification, Compounding Safety & USP Standards 14.2 Home Nutrition Support (HNS) & Care Transitions 14.3 Nutrition Support Policies, Product Shortages & Patient Education

15 Chapter 15: Professional Practice, Ethics & Interdisciplinary Care

15.1 Ethical Principles & Withholding/Withdrawing Artificial Nutrition 15.2 The Interdisciplinary Nutrition Support Team 15.3 Quality Improvement, Malnutrition Documentation & Clinical Standards 15.4 Critical Appraisal of Nutrition Research & Evidence

15.4 Critical Appraisal of Nutrition Research & Evidence

Key Takeaways Explain This Topic AI

Begin with a focused PICO question and choose the study design capable of answering it; design labels alone do not establish validity.

Assess selection, randomization, allocation concealment, blinding, attrition, exposure/outcome measurement, confounding, selective reporting, and whether analysis follows the assigned groups.

Interpret effect size with absolute risk, relative risk, confidence intervals, and clinical importance; statistical significance does not establish benefit or precision.

For diagnostic studies, interpret sensitivity, specificity, likelihood ratios, and predictive values in the intended population because prevalence changes predictive value.

Apply evidence by integrating certainty, benefit-harm balance, feasibility, cost, equity, patient values, and directness to the actual patient and nutrition-support setting.

Last updated: October 2026

15.4 Critical Appraisal of Nutrition Research & Evidence

Clinical Core: Evidence-based nutrition support is the integration of the best available research, clinical expertise, and patient values—not the mechanical adoption of an abstract conclusion. Appraisal asks three questions: Are the methods valid? How large and precise is the effect? Does it apply to this patient, product, dose, route, and setting?

Frame the Question Before Searching

Use PICO: patient or population, intervention, comparator, and outcome. Add time and setting when they matter. “Is fish oil useful?” is too broad. “In mechanically ventilated adults receiving EN during the first ICU week, does a specific omega-3–enriched formula versus an isocaloric standard high-protein formula reduce ventilator-free days or infection without increasing intolerance?” is testable.

Predefine patient-important outcomes. A change in a laboratory surrogate may not improve survival, function, infection, quality of life, or time at home. Distinguish efficacy under controlled conditions from effectiveness in routine care.

Match Design to the Question

Question Useful design Major threats

Therapy or prevention Randomized controlled trial Poor allocation concealment, crossover, missing outcomes, co-interventions

Prognosis or harm Prospective cohort; sometimes case-control for rare outcomes Confounding, selection, exposure misclassification

Diagnosis or screening Cross-sectional or cohort comparison with an appropriate reference standard Spectrum bias, verification bias, incorporation bias

Patient experience Qualitative study or mixed methods Inadequate sampling, shallow analysis, poor reflexivity

Evidence synthesis Systematic review and, when appropriate, meta-analysis Incomplete search, incompatible studies, publication bias

Randomization balances known and unknown prognostic factors on average, but it does not repair high attrition, unequal co-interventions, unblinded subjective outcomes, or selective reporting. Check whether the primary analysis followed intention-to-treat principles and whether the trial was registered before outcomes were known.

Observational studies may be the best feasible evidence for uncommon harms or long-term outcomes. Adjustment reduces measured confounding but cannot eliminate unmeasured confounding or reverse causation. A large sample does not convert a biased comparison into a randomized one.

Effect Size and Precision

Suppose infection occurs in 20% of the control group and 12% of the intervention group.

Relative risk = 0.12 0.20 = 0.60 \text{Relative risk} = \frac{0.12}{0.20} = 0.60 Relative risk = 0.20 0.12 ​ = 0.60

Absolute risk reduction = 0.20 − 0.12 = 0.08 ( 8 % ) \text{Absolute risk reduction} = 0.20 - 0.12 = 0.08\;(8\%) Absolute risk reduction = 0.20 − 0.12 = 0.08 ( 8% )

Number needed to treat = 1 0.08 = 12.5 → 13 \text{Number needed to treat} = \frac{1}{0.08} = 12.5 \rightarrow 13 Number needed to treat = 0.08 1 ​ = 12.5 → 13

The relative risk reduction is 40%, but the absolute effect—8 fewer infections per 100 treated—communicates baseline risk and is often more useful for decisions. Number needed to treat is rounded up to the next whole patient and should be presented with the time horizon and confidence interval.

A confidence interval describes the range of effects compatible with the data under the model. For a ratio measure, an interval crossing 1 includes no difference; for a mean difference, crossing 0 includes no difference. A narrow interval around a trivial effect may be precise but clinically unimportant. A wide interval may include meaningful benefit and harm even when the p value exceeds 0.05. A p value is not the probability that the null hypothesis is true and does not measure effect magnitude.

Diagnostic Evidence

Sensitivity is the proportion of people with the target condition who test positive; specificity is the proportion without it who test negative. Positive and negative predictive values depend strongly on prevalence. A screening tool validated in an ICU may perform differently in an ambulatory clinic because disease spectrum and prevalence change.

Likelihood ratios combine sensitivity and specificity and can update pretest odds to post-test odds. Appraise whether all participants received the same independent reference standard and whether test readers were blinded to the reference result. A nutrition assessment tool should not be declared diagnostic merely because it correlates with another imperfect tool.

Systematic Reviews and Heterogeneity

A systematic review should publish a reproducible question, eligibility criteria, comprehensive search, duplicate study selection, risk-of-bias assessment, and transparent synthesis. Meta-analysis is appropriate only when populations, interventions, comparators, and outcomes are sufficiently compatible.

Statistical heterogeneity measures such as I² describe inconsistency but do not explain it. Examine dose, timing, formula composition, baseline nutrition risk, route, setting, and outcome definitions. A pooled estimate can be misleading when clinically different products are treated as one intervention. Funnel-plot asymmetry may suggest publication bias but also has other explanations and is unreliable with few studies.

Certainty and Recommendation Strength

GRADE considers risk of bias, inconsistency, indirectness, imprecision, and publication bias, with possible upgrading of observational evidence for factors such as a large effect under defined circumstances. Certainty reflects confidence in an effect estimate. Recommendation strength additionally incorporates the balance of benefits and harms, patient values, resources, feasibility, acceptability, and equity. Therefore, certainty and recommendation strength are related but not identical.

Applying Evidence to Nutrition Support

Before applying a result, compare the study with the patient:

Was the patient population similar in age, disease, severity, organ function, and baseline nutrition risk?

Is the exact product, nutrient dose, route, timing, comparator, and background care available?

Are outcomes patient-important and measured over a relevant duration?

Do benefits outweigh access, infection, metabolic, aspiration, medication, cost, and burden risks?

Can the intervention be delivered reliably in this setting, and does it worsen inequity or caregiver burden?

Do the patient’s goals and preferences support the tradeoff?

Document uncertainty. If evidence is indirect or rapidly evolving, a monitored time-limited trial with predefined success and stop criteria may be more defensible than an indefinite intervention. Reassess when new evidence, safety alerts, products, or patient goals change.